Skip to main content
. 2021 Jul 5;12(6):1285–1292. doi: 10.1007/s41999-021-00534-z

Fig. 3.

Fig. 3

BENEFIC trial design [51, 58]. kMCT ketogenic medium-chain triglyceride, MCI mild cognitive impairment, MMSE mini-mental state examination, MoCA Montreal Cognitive Assessment, SD standard deviation